North China Pharmaceutical's (SHA:600812) isavuconazonium sulfate for injection received a drug registration certificate from China's National Medical Products Administration, according to a Shanghai bourse disclosure on Thursday.
The certificate is valid until May 26, 2030.
The pharmaceutical company invested 15.3 million yuan into the research and development of the drug, which is used for the treatment of adult invasive aspergillosis and mucormycosis, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.